5 results on '"Lora, David"'
Search Results
2. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
- Author
-
García-Pérez, Javier, Gonzalez-Perez, Maria, Castillo de la Osa, María, Borobia, Alberto M, Castaño, Luis, Bertrán, María Jesús, Campins, Magdalena, Portolés, Antonio, Lora, David, Bermejo, Mercedes, Conde-San Román, Patricia, Hernandez, Lourdes, Carcas, Antonio, Arana-Arri, Eunate, Tortajada, Marta, Fuentes, Inmaculada, Ascaso, Ana, García-Morales, María Teresa, de la Torre-Tarazona, Humberto Erick, Arribas, José-Ramón, Imaz-Ayo, Natale, Mellado-Pau, Eugènia, Agustí, Antonia, Pérez-Ingidua, Carla, Gómez de la Cámara, Agustín, Ochando, Jordi, Belda-Iniesta, Cristobal, Frías, Jesús, Alcamí, José, Perez-Olmeda, Mayte, CombiVacS study Group, Instituto de Salud Carlos III, Plan Nacional de I+D+i (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Unión Europea. Comisión Europea. H2020, Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas), European Commission, Institut Català de la Salut, [García-Pérez J] Unidad de Inmunopatología del SIDA, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [González-Pérez M] Laboratorio de Referencia en Inmunología, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Castillo de la Osa M] Laboratorio de Serología, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Borobia AM] Servicio de Farmacología Clínica, Departamento de Farmacología y Terapéutica, Facultad de Medicina, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain. [Castaño L] Biocruces Bizkaia, Hospital Universitario Cruces, CIBERDEM, CIBERER, Endo-ERN, UPV-EHU, Barakaldo, Spain. [Bertrán MJ] Servicio de Medicina Preventiva y Epidemiologia, Hospital Clínic de Barcelona, Barcelona, Spain. [Campins M] Servei de Medicina Preventiva i Epidemiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fuentes I] Unitat de Suport a la Investigació Clínica, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Agustí A] Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores] ,variants ,COVID-19 (Malaltia) - Prevenció ,SARS-CoV-2 ,Variants ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,heterologous vaccination ,General Medicine ,Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Neutralizing [CHEMICALS AND DRUGS] ,Antibodies ,Neutralisation ,Other subheadings::Other subheadings::/prevention & control [Other subheadings] ,neutralisation ,Heterologous vaccination ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,antibodies ,fenómenos del sistema inmunitario::formación de anticuerpos::inmunogenicidad vacunal [FENÓMENOS Y PROCESOS] ,Immune System Phenomena::Antibody Formation::Immunogenicity, Vaccine [PHENOMENA AND PROCESSES] ,Immunoglobulines ,aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos neutralizantes [COMPUESTOS QUÍMICOS Y DROGAS] ,COVID-19 (Malaltia) - Vacunació - Abstract
Background: The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. Methods: Between April 24 and 30, 2021, 676 adults primed with ChAdOx1-S were enrolled in five hospitals in Spain, and randomised to receive BNT162b2 as second dose (interventional group [IG]) or no vaccine (control group [CG]). Individuals from CG received BNT162b2 as second dose and also on day 28, as planned based on favourable results on day 14. Humoral immunogenicity, measured by immunoassay for SARS-CoV-2 receptor binding domain (RBD), antibody functionality using pseudovirus neutralisation assays for the reference (G614), Alpha, Beta, Delta, and Omicron variants, as well as cellular immune response using interferon-γ and IL-2 immunoassays were assessed at day 28 after BNT162b2 in both groups, at day 90 (planned only in the interventional group) and at day 180 (laboratory data cut-off on Nov 19, 2021). This study was registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739). Findings: In this secondary analysis, 664 individuals (441 from IG and 223 from CG) were included. At day 28 post vaccine, geometric mean titres (GMT) of RBD antibodies were 5616·91 BAU/mL (95% CI 5296·49-5956·71) in the IG and 7298·22 BAU/mL (6739·41-7903·37) in the CG (p < 0·0001). RBD antibodies titres decreased at day 180 (1142·0 BAU/mL [1048·69-1243·62] and 1836·4 BAU/mL [1621·62-2079·62] in the IG and CG, respectively; p < 0·0001). Neutralising antibodies also waned from day 28 to day 180 in both the IG (1429·01 [1220·37-1673·33] and 198·72 [161·54-244·47], respectively) and the CG (1503·28 [1210·71-1866·54] and 295·57 [209·84-416·33], respectively). The lowest variant-specific response was observed against Omicron-and Beta variants, with low proportion of individuals exhibiting specific neutralising antibody titres (NT50) >1:100 at day 180 (19% and 22%, respectively). Interpretation: Titres of RBD antibodies decay over time, similar to homologous regimes. Our findings suggested that delaying administration of the second dose did not have a detrimental effect after vaccination and may have improved the response obtained. Lower neutralisation was observed against Omicron and Beta variants at day 180. Funded by Instituto de Salud Carlos III (ISCIII). AMB, AJC, JO, and JF are members of the VACCELERATE (European Corona Vaccine Trial Accelerator Platform) Network, which aims to facilitate and accelerate the design and implementation of COVID-19 phase 2 and 3 vaccine trials. JO is a member of the INsTRuCT (Innovative Training in Myeloid Regulatory Cell Therapy) Consortium, a network of European scientists from academia and industry focused on developing innovative immunotherapies. This work is funded by Instituto de Salud Carlos III, a Spanish public body assigned to the Ministry of Science and Innovation that manages and promotes public clinical research related to public health. The Spanish Clinical Trials Platform is a public network funded by the Instituto de Salud Carlos III (grant numbers PTC20/00018 and PT17/0017), the State Plan for Research, Development, and Innovation 2013−16, the State Plan for Scientific and Technical Research and Innovation 2017−20, and the Subdirectorate General for Evaluation and Promotion of Research, Instituto de Salud Carlos III, cofinanced with FEDER funds. CombiVacS was designed under the umbrella of the VACCELERATE project. VACCELER ATE and INsTRuCT received funding from the EU’s Horizon 2020 Research and Innovation Programme (grant agreement numbers 101037867 and 860003). The Instituto de Salud Carlos III is the Spanish partner in the VACCELERATE project. This work is partially funded by Institute of Health Carlos III (Instituto de Salud Carlos III − ISCIII −), (grants PI19CIII/00004 to JA and PI21CIII/00025 to MPO and JGP), and COVID-19 FUND (grants COV20/00679 and COV20/00072 to MPO and JA) and CIBERINFEC, co-financed by the European Regional Development Fund (FEDER) “A way to make Europe”. The authors thank all trial participants, the international data safety monitoring board (Appendix 1 p 23), and the trial steering committee (Appendix 1 pp 24−25). The authors thank Esther Prieto for editorial assistance and writing support (employed by Hospital Universitario La Paz; funded by the Instituto de Salud Carlos III, grant number PCT20/00018) and María Castillo-de la Osa (PEJ2018-004557-A) for excellent technical assistance. Sí
- Published
- 2022
3. Additional file of Endometrial scratch vs no intervention in egg donation cycles: the ENDOSCRATCH trial protocol
- Author
-
Izquierdo, Alexandra, De La Fuente, Laura, Spies, Katharina, Rayward, Jennifer, López, Lourdes, Lora, David, and Galindo, Alberto
- Subjects
integumentary system - Abstract
Additional file of Endometrial scratch vs no intervention in egg donation cycles: the ENDOSCRATCH trial protocol
- Published
- 2021
- Full Text
- View/download PDF
4. Systematic review and meta-analysis comparing Adjustable Transobturator Male System (ATOMS) and Adjustable Continence Therapy (ProACT) for male stress incontinence
- Author
-
Angulo Cuesta, Javier, Schönburg, Sandra, Giammò, Alessandro, Abellán, Francisco J., Arance Gil, José Ignacio, and Lora, David
- Subjects
Neoplasias de la próstata ,Urología ,Cáncer ,Tecnología médica ,Incontinencia urinaria - Abstract
Background and purpose: Urinary incontinence is one of the most serious complications of prostate cancer treatment. The objective of this study was to assess efficacy and safety of Adjustable Transobturator Male System (ATOMS) compared to Adjustable Continence Therapy (proACT) for male stress urinary incotinence according to literature findings. Material and methods: A systematic review and meta-analysis on adjustable devices ATOMS and ProACT is presented. Studies on female or neurogenic incontinence were excluded. Differences between ATOMS and proACT in primary objective: dryness status (no-pad or one safety pad/day) after initial device adjustment, and in secondary objectives: improvement, satisfaction, complications and device durability, were estimated using random-effect model. Statistical heterogeneity among studies included in the meta-analysis was assessed using tau2, Higgins´s I2 statistics and Cochran´s Q test. Results: Combined data of 41 observational studies with 3059 patients showed higher dryness (68 vs. 55%; p = .01) and improvement (91 vs. 80%; p = .007) rate for ATOMS than ProACT. Mean pad-count (-4 vs. -2.5 pads/day; p = .005) and pad-test decrease (-425.7 vs. -211.4 cc; p < .0001) were also significantly lower. Satisfaction was higher for ATOMS (87 vs. 56%; p = .002) and explant rate was higher for proACT (5 vs. 24%; p < .0001). Complication rate for ProACT was also higher, but not statistically significant (17 vs. 26%; p = .07). Mean follow-up was 25.7 months, lower for ATOMS than ProACT (20.8 vs. 30.6 months; p = .02). The rate of working devices favoured ATOMS at 1-year (92 vs. 76; p < .0001), 2-years (85 vs. 61%; p = .0008) and 3-years (81 vs. 58%; p = .0001). Significant heterogeneity was evidenced, due to variable incontinence severity baseline, difficulties for a common reporting of complications, different number of adjustments and time of follow-up and absence of randomized studies. Conclusions: Despite the limitations that studies available are exclusively descriptive and the follow-up is limited, literature findings confirm ATOMS is more efficacious, with higher patient satisfaction and better durability than ProACT to treat male stress incontinence. Sin financiación 2.740 JCR (2019) Q2, 27/71 Multidisciplinary Sciences 1.023 SJR (2019) Q1, 10/148 Multidisciplinary No data IDR 2019 UEM
- Published
- 2019
5. Development of a predictive model of hospitalization in primary care patients with heart failure
- Author
-
García-Olmos, Luis, Aguilar, Río, Lora, David, Carmona, Montse, Alberquilla, Ángel, García-Caballero, Rebeca, Sánchez Gómez, Luis, The Chic Group, UAM. Departamento de Medicina, Instituto de Investigación del Hospital de La Princesa (IP), Instituto de Salud Carlos III, and Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
- Subjects
Male ,Pulmonology ,Pérdida de la salud ,Emotions ,Social Sciences ,030204 cardiovascular system & hematology ,Logistic regression ,Endocrinology ,Mathematical and Statistical Techniques ,0302 clinical medicine ,Quality of life ,Risk Factors ,Medicine and Health Sciences ,Psychology ,Medicine ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,COPD ,Multidisciplinary ,Statistics ,Models, Cardiovascular ,Middle Aged ,Hospitals ,Hospitalization ,Physical Sciences ,Hospitalizaciones ,Female ,Pacientes ,Research Article ,Cohort study ,medicine.medical_specialty ,Endocrine Disorders ,Medicina ,Science ,Chronic Obstructive Pulmonary Disease ,Cardiology ,Research and Analysis Methods ,03 medical and health sciences ,Diabetes mellitus ,Diabetes Mellitus ,Humans ,Statistical Methods ,Aged ,Heart Failure ,Hospitalizations ,Primary Health Care ,business.industry ,Biology and Life Sciences ,Métodos de obsevación ,medicine.disease ,Health Care ,Clinical trial ,Health Care Facilities ,Metabolic Disorders ,Heart failure ,Emergency medicine ,Quality of Life ,Pacientes riesgo hospitalización ,business ,Mathematics ,Forecasting - Abstract
Background Heart failure (HF) is the leading cause of hospitalization in people over age 65. Predictive hospital admission models have been developed to help reduce the number of these patients. Aim To develop and internally validate a model to predict hospital admission in one-year for any non-programmed cause in heart failure patients receiving primary care treatment. Design and setting Cohort study, prospective. Patients treated in family medicine clinics. Methods Logistic regression analysis was used to estimate the association between the predictors and the outcome, i.e. unplanned hospitalization over a 12-month period. The predictive model was built in several steps. The initial examination included a set of 31 predictors. Bootstrapping was used for internal validation. Results The study included 251 patients, 64 (25.5%) of whom were admitted to hospital for some unplanned cause over the 12 months following their date of inclusion in the study. Four predictive variables of hospitalization were identified: NYHA class III-IV, OR (95% CI) 2.46 (1.23–4.91); diabetes OR (95% CI) 1.94 (1.05–3.58); COPD OR (95% CI) 3.17 (1.45–6.94); MLHFQ Emotional OR (95% CI) 1.07 (1.02–1.12). AUC 0.723; R2N 0.17; Hosmer-Lemeshow 0.815. Internal validation AUC 0.706.; R2N 0.134 Conclusion This is a simple model to predict hospitalization over a 12-month period based on four variables: NYHA functional class, diabetes, COPD and the emotional dimension of the MLHFQ scale. It has an acceptable discriminative capacity enabling the identification of patients at risk of hospitalization., This study was financed by the Health Research Fund (FIS), grant no. PI 14/01677 and co-financed with ERDF funds from the European Union: REDISSEC - Project ISCIII (Red de Investigación en Enfermedades Crónicas del Servicio de Salud - Instituto de Salud Carlos III) concession no. RD16/0001/0004. The Foundation for Biosanitary Research and Innovation in Primary Health Care (FIIBAP) financed the costs of publishing the article
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.